FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295227181> ?p ?o ?g. }

• W4295227181 endingPage "S147" @default.
• W4295227181 startingPage "S147" @default.
• W4295227181 abstract "<b>Objectives:</b> Chemotherapy is often ineffective in advanced-stage and aggressive histologic subtypes of endometrial cancer. Overexpression of the receptor tyrosine kinase AXL has been found to be associated with therapeutic resistance, metastasis, and poor prognosis. The mechanism of how inhibition of AXL improves response to chemotherapy is still largely unknown. We aimed to determine whether treatment with AVB-500, a selective inhibitor of <i>GAS6</i>-AXL, improves endometrial cancer cell sensitivity to chemotherapy, particularly through metabolic changes. <b>Methods:</b> Immunohistochemistry (IHC) was performed on a tissue microarray containing specimens from patients with primary and metastatic uterine serous carcinoma. Blind scoring was performed by two reviewers. Kaplan-Meier methods were used to generate time-to-event curves. Cell viability was performed with high-grade endometrial, chemo-resistant cell lines, ARK1 and PUC198. Cells were treated with paclitaxel and with AVB-500+paclitaxel. Intraperitoneal (IP) ARK1 or PUC198 tumors were treated with vehicle, AVB-500, paclitaxel, or AVB-500+paclitaxel. A Seahorse Analyzer was used for glycolytic rate assays. Isotope tracing was used for <i>in vivo</i> metabolite abundance quantification. <b>Results:</b> We found that both <i>GAS6</i> and AXL expression were higher by IHC in tumors with a poor response to chemotherapy compared to tumors with a good response to chemotherapy (<i>GAS6</i>: 40.9% vs 30.4%, p=0.012; AXL: 60.7% vs 42.7%, p=0.013). Median PFS and OS were longer in patients with low <i>GAS6</i> expressing tumors compared to high <i>GAS6</i> expressing tumors (PFS: 33.6 mo vs 10.6 mo, p=0.003; OS: 39.5 mo vs 27.7 mo, p=0.003). We showed that chemotherapy-resistant endometrial cancer cell lines, ARK1 and PUC198, had improved sensitivity and synergy with paclitaxel when treated in combination with AVB-500. ARK1 and PUC198 <i>in vivo</i> IP models had significantly fewer tumors (ARK1: 2.8 vs 7.9, p=0.028; PUC198: p=0.029) and decreased tumor weight (ARK1: p<0.001; PUC198: p=0.006) when treated with AVB-500+paclitaxel versus paclitaxel alone. Treatment with AVB-500 + paclitaxel decreased AKT signaling, which resulted in a decrease in basal glycolysis. Finally, treatment with AVB-500 + paclitaxel decreased multiple glycolytic metabolites, including fructose-1,6-bisphosphate (p=0.002), 3-phosphoglyceric acid (p=0.014), phosphoenolpyruvate (p=0.013), and lactate (p=0.024) versus treatment with paclitaxel alone. <b>Conclusions:</b> Our study provides a strong preclinical rationale for combining AVB-500 with paclitaxel in aggressive endometrial cancer models. Additionally, the continued identification of viable biomarkers is critical to the success of targeted therapies, such as AVB-500. Given AXL's role in glucose homeostasis, one or more glycolytic intermediates may prove to be a useful biomarker to help predict sensitivity in patients, thus tailoring who would benefit from this treatment combination." @default.
• W4295227181 created "2022-09-12" @default.
• W4295227181 creator A5002033312 @default.
• W4295227181 creator A5015536044 @default.
• W4295227181 creator A5019833062 @default.
• W4295227181 creator A5024497385 @default.
• W4295227181 creator A5027513211 @default.
• W4295227181 creator A5031718333 @default.
• W4295227181 creator A5037710265 @default.
• W4295227181 creator A5038806823 @default.
• W4295227181 creator A5044402423 @default.
• W4295227181 creator A5047232352 @default.
• W4295227181 creator A5050508199 @default.
• W4295227181 creator A5051775831 @default.
• W4295227181 creator A5065690865 @default.
• W4295227181 creator A5068154333 @default.
• W4295227181 creator A5068335479 @default.
• W4295227181 creator A5076087889 @default.
• W4295227181 creator A5080722354 @default.
• W4295227181 creator A5070894579 @default.
• W4295227181 date "2022-08-01" @default.
• W4295227181 modified "2023-09-23" @default.
• W4295227181 title "GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis (276)" @default.
• W4295227181 doi "https://doi.org/10.1016/s0090-8258(22)01497-4" @default.
• W4295227181 hasPublicationYear "2022" @default.
• W4295227181 type Work @default.
• W4295227181 citedByCount "0" @default.
• W4295227181 crossrefType "journal-article" @default.
• W4295227181 hasAuthorship W4295227181A5002033312 @default.
• W4295227181 hasAuthorship W4295227181A5015536044 @default.
• W4295227181 hasAuthorship W4295227181A5019833062 @default.
• W4295227181 hasAuthorship W4295227181A5024497385 @default.
• W4295227181 hasAuthorship W4295227181A5027513211 @default.
• W4295227181 hasAuthorship W4295227181A5031718333 @default.
• W4295227181 hasAuthorship W4295227181A5037710265 @default.
• W4295227181 hasAuthorship W4295227181A5038806823 @default.
• W4295227181 hasAuthorship W4295227181A5044402423 @default.
• W4295227181 hasAuthorship W4295227181A5047232352 @default.
• W4295227181 hasAuthorship W4295227181A5050508199 @default.
• W4295227181 hasAuthorship W4295227181A5051775831 @default.
• W4295227181 hasAuthorship W4295227181A5065690865 @default.
• W4295227181 hasAuthorship W4295227181A5068154333 @default.
• W4295227181 hasAuthorship W4295227181A5068335479 @default.
• W4295227181 hasAuthorship W4295227181A5070894579 @default.
• W4295227181 hasAuthorship W4295227181A5076087889 @default.
• W4295227181 hasAuthorship W4295227181A5080722354 @default.
• W4295227181 hasConcept C101544691 @default.
• W4295227181 hasConcept C121608353 @default.
• W4295227181 hasConcept C126322002 @default.
• W4295227181 hasConcept C142724271 @default.
• W4295227181 hasConcept C143998085 @default.
• W4295227181 hasConcept C157333092 @default.
• W4295227181 hasConcept C170493617 @default.
• W4295227181 hasConcept C172811965 @default.
• W4295227181 hasConcept C204232928 @default.
• W4295227181 hasConcept C2776694085 @default.
• W4295227181 hasConcept C2777088508 @default.
• W4295227181 hasConcept C2777292972 @default.
• W4295227181 hasConcept C2779013556 @default.
• W4295227181 hasConcept C502942594 @default.
• W4295227181 hasConcept C5364575 @default.
• W4295227181 hasConcept C71924100 @default.
• W4295227181 hasConceptScore W4295227181C101544691 @default.
• W4295227181 hasConceptScore W4295227181C121608353 @default.
• W4295227181 hasConceptScore W4295227181C126322002 @default.
• W4295227181 hasConceptScore W4295227181C142724271 @default.
• W4295227181 hasConceptScore W4295227181C143998085 @default.
• W4295227181 hasConceptScore W4295227181C157333092 @default.
• W4295227181 hasConceptScore W4295227181C170493617 @default.
• W4295227181 hasConceptScore W4295227181C172811965 @default.
• W4295227181 hasConceptScore W4295227181C204232928 @default.
• W4295227181 hasConceptScore W4295227181C2776694085 @default.
• W4295227181 hasConceptScore W4295227181C2777088508 @default.
• W4295227181 hasConceptScore W4295227181C2777292972 @default.
• W4295227181 hasConceptScore W4295227181C2779013556 @default.
• W4295227181 hasConceptScore W4295227181C502942594 @default.
• W4295227181 hasConceptScore W4295227181C5364575 @default.
• W4295227181 hasConceptScore W4295227181C71924100 @default.
• W4295227181 hasLocation W42952271811 @default.
• W4295227181 hasOpenAccess W4295227181 @default.
• W4295227181 hasPrimaryLocation W42952271811 @default.
• W4295227181 hasRelatedWork W2079075723 @default.
• W4295227181 hasRelatedWork W2124777963 @default.
• W4295227181 hasRelatedWork W2149942973 @default.
• W4295227181 hasRelatedWork W2560005056 @default.
• W4295227181 hasRelatedWork W2568917916 @default.
• W4295227181 hasRelatedWork W2738852905 @default.
• W4295227181 hasRelatedWork W2776647540 @default.
• W4295227181 hasRelatedWork W2908683657 @default.
• W4295227181 hasRelatedWork W4294292783 @default.
• W4295227181 hasRelatedWork W4307911008 @default.
• W4295227181 hasVolume "166" @default.
• W4295227181 isParatext "false" @default.
• W4295227181 isRetracted "false" @default.
• W4295227181 workType "article" @default.